South African women-led healthtech startup Alignd has secured investment from venture capital firm Knife Capital to expand its healthcare services into maternity and kidney care.

Founded in 2018 and based in Cape Town, Alignd is led by CEO Dr Lungi Nyathi. The company uses an outcome-based healthcare model designed to improve patient care while helping medical insurers manage costs.

The investment, made through Knife Fund III, will support Alignd as it takes this approach into two areas where early intervention and coordinated care can make a significant difference: maternal health and chronic kidney disease. The amount of the investment has not been disclosed.

Alignd plans expansion into maternity and kidney care

Alignd’s model focuses on the quality and outcomes of treatment rather than paying healthcare providers mainly for the number of procedures or services they deliver. It aims to encourage more coordinated care, improve patient experiences and reduce unnecessary healthcare spending.

The company plans to use the new funding to develop programmes that address challenges in maternity and kidney care.

In maternity care, Alignd aims to improve health outcomes for mothers and newborns through better coordination between healthcare providers and more focused patient support.

In kidney care, the company plans to focus on managing chronic kidney disease, slowing its progression and helping patients preserve kidney function. The approach is intended to support earlier intervention and reduce the costs associated with advanced kidney disease and long-term treatment.

The expansion builds on Alignd’s experience in palliative care, where its outcome-based model has already demonstrated potential to improve care while reducing costs for medical schemes.

Palliative care programme reports R600 million in savings

Alignd works with a network of more than 500 healthcare providers to support patients with serious or life-limiting illnesses, including those receiving care at home or in hospices.

According to the company, its palliative care programme has helped medical insurers save approximately R600 million (about US$36 million).

The programme also reports that around two-thirds of enrolled patients died at home or in a hospice. Chemotherapy treatment during the final month of life declined by 33%, reflecting a shift towards care that considers patients’ needs, comfort and quality of life.

Alignd says its programme reaches more than 3.3 million beneficiaries across seven medical schemes, including GEMS, Fedhealth and Bonitas.

These results provide the foundation for the company’s planned expansion into other areas of healthcare.

Knife Capital backs Alignd’s healthcare model

The investment from Knife Capital signals confidence in Alignd’s approach to improving healthcare delivery through a greater focus on patient outcomes.

Catherine Young, a partner at Knife Capital, has highlighted the work of Alignd’s women-founded team and the impact of its healthcare model.

Alignd operates through a business-to-business model, partnering with medical schemes and healthcare providers to deliver and coordinate services for their members.

As the company moves into maternity and kidney care, it will seek to apply the lessons from its palliative care programme to new patient groups and healthcare needs.

For Dr Nyathi and her team, the next phase is about taking a model that has shown results in palliative care and extending it to areas where better-coordinated treatment could improve lives while easing pressure on healthcare systems.